高通量人类肠道免疫共同培养模型用于评估炎症性肠病抗炎疗法
bioRxiv : the preprint server for biology
|June 4, 2025
概括
使用肠道细胞和巨细胞的新型共同培养模型有效地模仿炎症性肠病 (IBD) 病理学. 这种与人类相关的系统显示出新抗炎药物的高通量查有望加速IBD治疗开发.
科学领域:
- 胃肠道学和免疫学
- 在体外建模模型.
- 药物发现 药物发现
背景情况:
- 目前的炎症性肠病 (IBD) 治疗方法面临长期的无效性和患者不响应.
- 现有的IBD药物开发的动物模型表现出显著的物种间变异性和差的可翻译性.
- 试验室模型往往缺乏复杂性,无法准确地代表IBD病因学至关重要的免疫-肠上皮相互作用.
研究的目的:
- 开发一个复杂的体外共同培养系统,模拟IBD中的免疫-上皮相互作用.
- 将天生的免疫信号纳入肠道细胞模型,以提高疾病相关性.
- 建立一个平台,用于针对IBD的抗炎药物的高通量查.
主要方法:
- 在TranswellTM系统中利用了与THP-1衍生的巨细胞共同培养的RepliGut®-Planar横向结肠细胞.
- 在受刺激和不受刺激的巨细胞条件下评估上皮屏障完整性 (TEER) 和细胞活力.
- 评估了抗IBD疗法 (adalimumab,tofacitinib) 在共同培养模型中减轻炎症反应的疗效.
主要成果:
- 与未刺激的巨细胞共同培养维持了上皮质完整性和细胞活力.
- 与LPS + IFN-γ刺激的巨细胞共同培养会损害上皮质完整性和活力,反映IBD病理.
- 刺激的巨共同培养导致炎症性细胞因子的释放增加,这种释放因阿达利穆马布和托法西提尼布治疗而减少.
结论:
- 开发的共同培养系统准确地复制了IBD中观察到的关键的先天性炎症信号和上皮反应.
- 该模型表明其能够验证现有的抗炎性IBD治疗方法的预防作用.
- 该系统的可复制性和可扩展性支持其在新型IBD疗法高通量药物查中的应用.
更多相关视频
06:57Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
9.2K
07:39Author Spotlight: Investigating the Effects of Compounds on Intestinal Tissue Using 3D Human Cell Line Models
Published on: September 1, 2023
1.3K
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
